Boston Scientific Corp. (BSX) Tops Q3 EPS by 6c; Adjusts FY11 Outlook, Guides Q411
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Price: $51.88 +0.89%
Financial Fact:
Selling, general and administrative expenses: 772M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Selling, general and administrative expenses: 772M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Boston Scientific Corp. (NYSE: BSX) reported Q3 EPS of $0.15, $0.06 better than the analyst estimate of $0.09. Revenue for the quarter came in at $1.87 billion versus the consensus estimate of $1.91 billion.
Boston Scientific Corp. sees Q4 2011 EPS of $0.13-$0.16, versus the consensus of $0.10. Boston Scientific Corp. sees Q4 2011 revenue of $1.85-$1.95 billion, versus the consensus of $1.97 billion.
Boston Scientific Corp. sees FY2011 EPS of $0.67-$0.70, versus prior guidance of $0.64-$0.70 and the consensus of $0.45. Boston Scientific Corp. sees FY2011 revenue of $7.624-$7.724 billion, versus the consensus of $7.77 billion.
Boston Scientific Corp. sees Q4 2011 EPS of $0.13-$0.16, versus the consensus of $0.10. Boston Scientific Corp. sees Q4 2011 revenue of $1.85-$1.95 billion, versus the consensus of $1.97 billion.
Boston Scientific Corp. sees FY2011 EPS of $0.67-$0.70, versus prior guidance of $0.64-$0.70 and the consensus of $0.45. Boston Scientific Corp. sees FY2011 revenue of $7.624-$7.724 billion, versus the consensus of $7.77 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
- Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
